Anti-clotting drug Xarelto matches standard therapy in a Phase III trial

08/4/2010 | Bloomberg

Bayer's blood thinner Xarelto appeared to work as well as the standard-therapy combination of Sanofi-Aventis' Lovenox and warfarin in preventing deep vein thrombosis during a late-stage study. Patients who received Xarelto were as likely as those given the standard treatment to develop severe and uncontrolled bleeding.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN